TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor.
de Kouchkovsky I, Zhang L, Philip EJ, Wright F, Kim DM, Natesan D, Kwon D, Ho H, Ho S, Chan E, Porten SP, Wong AC, Desai A, Huang FW, Chou J, Oh DY, Pruthi RS, Fong L, Small EJ, Friedlander TW, Koshkin VS.
de Kouchkovsky I, et al.
J Immunother Cancer. 2021 May;9(5):e002127. doi: 10.1136/jitc-2020-002127.
J Immunother Cancer. 2021.
PMID: 33980590
Free PMC article.